Chemotherapy for the treatment of standard risk adult medulloblastomas

2024-513243-85-00 Therapeutic exploratory (Phase II) Ongoing, recruiting

Start 3 Feb 2023 · Status Ongoing, recruiting · 1 EU/EEA countries · 7 sites

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ongoing, recruiting
Participants planned 45
Countries 1
Sites 7

Adult medulloblastoma

Key facts

Sponsor
CHRU De Nancy
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 Feb 2023 → ongoing
Decision date (initial)
2024-05-24
Transition trial
Yes
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2024-513243-85-00
EudraCT number
2012-002803-16
ClinicalTrials.gov
NCT01857453

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Adult medulloblastoma

VersionLevelCodeTermSystem organ class
20.0 PT 10027107 Medulloblastoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

CHRU De Nancy

Sponsor organisation
CHRU De Nancy
Address
Co N°34, 29 Avenue Du Mal De Lattre De Tassigny, Bp 60034 29 Avenue Du Mal De Lattre De Tassigny Bp 60034
City
Nancy Cedex
Postcode
54035
Country
France

Scientific contact point

Organisation
CHRU De Nancy
Contact name
Pr. Luc TAILLANDIER

Public contact point

Organisation
CHRU De Nancy
Contact name
M. El Mehdi SIAGHY, directeur de la Recherche et de l'Innovation

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 45 7
Rest of world 0

Investigational sites

France

7 sites · Ongoing, recruiting
Centre Hospitalier Regional De Marseille
Neuro-Oncologie, 80 Rue Brochier, 13005, Marseille
Centre Hospitalier Universitaire De Lille
Neurochirurgie, 2 Avenue Oscar Lambret, Cs 70001, Lille Cedex
Assistance Publique Hopitaux De Paris
Neurologie, 47 Boulevard De L Hopital, 75651, Paris Cedex 13
Centre Hospitalier Universitaire Amiens Picardie
Oncologie, 1 Place Victor Pauchet, 80080, Amiens
Centre Leon Berard
Radiothérapie, 28 Rue Laennec, 69008, Lyon
Institut Universitaire Du Cancer Toulouse-Oncopole
Radiothérapie, 1 Avenue Irene Joliot Curie, 31059, Toulouse Cedex 9
Institut Regional Du Cancer De Montpellier
Radiothérapie, 208 Avenue Des Apothicaires, 34298, Montpellier Cedex 5

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2013-04-10 2013-04-10

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-26741

Halt date
2023-02-03
Member states concerned
France
Publication date
2024-05-29
Reason
Sponsor decision
Explanation
arrêt temporaire des inclusions pour suspicion de manque d’efficacité
Follow-up measures
Mise en œuvre d’une mesure urgente de sécurité
Benefit-risk balance changed
No
Treatment stopped
No

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-02 France Acceptable
2024-05-24
2024-05-24